These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors. Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676 [TBL] [Abstract][Full Text] [Related]
9. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709 [TBL] [Abstract][Full Text] [Related]
10. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497 [TBL] [Abstract][Full Text] [Related]
11. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907 [TBL] [Abstract][Full Text] [Related]
12. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697 [TBL] [Abstract][Full Text] [Related]
13. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948 [TBL] [Abstract][Full Text] [Related]
14. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126. Gao J; Niwa K; Takemura M; Sun W; Onogi K; Wu Y; Seishima M; Mori H; Tamaya T Int J Oncol; 2005 Mar; 26(3):737-44. PubMed ID: 15703831 [TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. Paternot S; Roger PP Cancer Res; 2009 Jun; 69(11):4577-81. PubMed ID: 19458076 [TBL] [Abstract][Full Text] [Related]
16. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Gysin S; Lee SH; Dean NM; McMahon M Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308 [TBL] [Abstract][Full Text] [Related]
17. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population. Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme. Albert L; Karsy M; Murali R; Jhanwar-Uniyal M Cancer Genomics Proteomics; 2009; 6(5):255-61. PubMed ID: 19996130 [TBL] [Abstract][Full Text] [Related]
19. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143 [TBL] [Abstract][Full Text] [Related]
20. The mitogen-activated/extracellular signal-regulated kinase kinase 1/2 inhibitor U0126 induces glial fibrillary acidic protein expression and reduces the proliferation and migration of C6 glioma cells. Lind CR; Gray CW; Pearson AG; Cameron RE; O'Carroll SJ; Narayan PJ; Lim J; Dragunow M Neuroscience; 2006 Sep; 141(4):1925-33. PubMed ID: 16809005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]